Why You Shouldn't Bet Against Sanofi (SNY) Stock

11.04.25 15:07 Uhr

Werte in diesem Artikel
Aktien

89,58 EUR 1,38 EUR 1,56%

Indizes

10.210,8 PKT -98,3 PKT -0,95%

7.104,8 PKT -21,2 PKT -0,30%

499,3 PKT -1,3 PKT -0,26%

4.787,2 PKT -31,7 PKT -0,66%

1.399,9 PKT -3,9 PKT -0,28%

3.519,6 PKT -17,6 PKT -0,50%

7.063,2 PKT -198,9 PKT -2,74%

5.386,6 PKT -10,4 PKT -0,19%

4.097,7 PKT -9,5 PKT -0,23%

One stock that might be an intriguing choice for investors right now is Sanofi SNY. This is because this security in the Large Cap Pharmaceuticals space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Large Cap Pharmaceuticals space as it currently has a Zacks Industry Rank of 71 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there. Meanwhile, Sanofi is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.Sanofi Price and Consensus Sanofi price-consensus-chart | Sanofi QuoteIn fact, over the past month, current quarter estimates have risen from 87 cents per share to 89 cents per share, while current year estimates have risen from $4.21 per share to $4.34 per share. The company currently carries a Zacks Rank #3 (Hold), which is also a favorable signal. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.So, if you are looking for a decent pick in a strong industry, consider Sanofi. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Sanofi

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Sanofi

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Sanofi S.A.

Wer­bung

Analysen zu Sanofi S.A.

DatumRatingAnalyst
09.04.2025Sanofi BuyJefferies & Company Inc.
07.04.2025Sanofi HoldDeutsche Bank AG
03.04.2025Sanofi OutperformBernstein Research
25.03.2025Sanofi NeutralJP Morgan Chase & Co.
21.03.2025Sanofi NeutralGoldman Sachs Group Inc.
DatumRatingAnalyst
09.04.2025Sanofi BuyJefferies & Company Inc.
03.04.2025Sanofi OutperformBernstein Research
11.03.2025Sanofi OutperformBernstein Research
10.03.2025Sanofi BuyJefferies & Company Inc.
05.03.2025Sanofi BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
DatumRatingAnalyst
07.04.2025Sanofi HoldDeutsche Bank AG
25.03.2025Sanofi NeutralJP Morgan Chase & Co.
21.03.2025Sanofi NeutralGoldman Sachs Group Inc.
04.03.2025Sanofi HoldDeutsche Bank AG
14.02.2025Sanofi NeutralJP Morgan Chase & Co.
DatumRatingAnalyst
18.12.2024Sanofi SellDeutsche Bank AG
17.12.2024Sanofi SellDeutsche Bank AG
06.12.2024Sanofi SellDeutsche Bank AG
03.12.2024Sanofi SellDeutsche Bank AG
28.10.2024Sanofi SellDeutsche Bank AG

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Sanofi S.A. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen